Bausch Health Companies Inc. (TSE:BHC – Get Rating) – Stock analysts at Zacks Research raised their Q3 2022 earnings per share estimates for shares of Bausch Health Companies in a research note issued to investors on Tuesday, September 20th. Zacks Research analyst E. Bagri now forecasts that the company will post earnings of $1.34 per share for the quarter, up from their prior forecast of $1.33. The consensus estimate for Bausch Health Companies’ current full-year earnings is $6.17 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2022 earnings at $1.23 EPS, FY2022 earnings at $4.27 EPS, Q1 2023 earnings at $1.37 EPS, Q2 2023 earnings at $1.30 EPS, Q3 2023 earnings at $1.32 EPS, Q4 2023 earnings at $1.08 EPS, Q2 2024 earnings at $1.54 EPS and FY2024 earnings at $6.20 EPS.
Bausch Health Companies (TSE:BHC – Get Rating) last posted its earnings results on Tuesday, August 9th. The company reported C$0.71 earnings per share for the quarter, missing analysts’ consensus estimates of C$1.15 by C($0.44). The business had revenue of C$2.51 billion during the quarter, compared to analysts’ expectations of C$2.63 billion.
Bausch Health Companies Stock Performance
Bausch Health Companies stock opened at C$9.63 on Thursday. The company has a quick ratio of 0.46, a current ratio of 1.08 and a debt-to-equity ratio of 8,622.13. The company has a market capitalization of C$3.48 billion and a P/E ratio of 50.68. The stock’s 50 day moving average is C$8.54 and its 200 day moving average is C$15.61. Bausch Health Companies has a twelve month low of C$5.10 and a twelve month high of C$37.42.
In other news, Director Joseph Papa sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of C$9.84, for a total transaction of C$983,534.70. Following the completion of the transaction, the director now owns 934,594 shares in the company, valued at C$9,192,056.29.
About Bausch Health Companies
Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.